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Introduction {#sec1}
============

Transcriptome surveys have uncovered tens of thousands of mammalian transcripts longer than 200 nucleotides that have low protein-coding potential ([@bib8], [@bib12], [@bib18]). A small fraction of these long non-coding RNAs (lncRNAs) have been shown to control gene expression by modulating chromosomal structure, transcription, splicing, mRNA transport, stability, or translation ([@bib9], [@bib11], [@bib17], [@bib28], [@bib31], [@bib60], [@bib63]). Specific lncRNAs have thus been implicated in various key processes, including random X chromosome inactivation, imprinting, the cell cycle, organogenesis, differentiation, pluripotency, and cancer progression ([@bib19], [@bib20], [@bib21], [@bib25], [@bib26], [@bib40], [@bib46], [@bib48], [@bib55]). Despite these wide-ranging biological roles, the fraction of lncRNAs that is genuinely functional and the true impact of lncRNAs in human biology and disease remain poorly understood.

Pancreatic β cells regulate glucose homeostasis by secreting insulin and play a central role in the pathogenesis of major forms of diabetes mellitus. Recently, more than 1,100 lncRNAs were identified in human pancreatic islets and purified β cells ([@bib32]) as well as in mouse pancreatic islet cells ([@bib6], [@bib27], [@bib32]). A large fraction of human β cell lncRNAs are cell-specific, and several are known to be activated during β cell differentiation ([@bib32]). This cellular specificity has also been noted for lncRNAs in other cell types ([@bib7], [@bib12]) and points to the possibility that lncRNAs may regulate genetic programs important for lineage-specific differentiation or specialized cellular functions. Further, several β cell lncRNAs were shown to be regulated by extracellular glucose concentrations, suggesting a potential role of lncRNAs in the functional adaptation of β cells to increased insulin secretory demands ([@bib32]). Some islet lncRNAs map to loci that contain polygenic or Mendelian defects associated with human diabetes, whereas selected lncRNAs show deregulation in islets from organ donors with human type 2 diabetes (T2D) ([@bib14], [@bib32]). Collectively, these properties define a newly identified class of candidate regulators of β cell differentiation and function, with potential implications for human diabetes mellitus. However, the true relevance of β cell lncRNAs depends on whether they elicit a physiological function in human β cells, which remains to be addressed systematically.

In the current study, we have focused on a set of lncRNAs that show restricted expression in human pancreatic β cells and have tested the hypothesis that they regulate β cell gene expression. Our studies have uncovered a regulatory network in which lineage-specific lncRNAs and transcription factors (TFs) control common genes. Furthermore, we show that lncRNAs frequently regulate genes associated with clusters of islet enhancers, which have previously been shown to be the primary functional targets of islet-specific TFs. We performed a detailed analysis of a specific lncRNA named *PLUTO*, which controls *PDX1*, a master regulator of pancreas development and β cell differentiation and, thereby, modulates the *PDX1*-dependent transcriptional program. Finally, we show that *PLUTO* and *PDX1* are downregulated in islets from organ donors with type 2 diabetes or impaired glucose tolerance, suggesting a potential role in human diabetes.

Results {#sec2}
=======

Human β Cell lncRNA Knockdowns Cause Profound Transcriptional Phenotypes {#sec2.1}
------------------------------------------------------------------------

To directly test the regulatory function of pancreatic β cell lncRNAs, we carried out loss-of-function experiments in a glucose-responsive human islet β cell line, EndoC-βH1 ([@bib43]). We chose a human model because only some human lncRNAs are evolutionary conserved ([@bib12], [@bib32], [@bib35], [@bib37]), and we perturbed the function of lncRNAs through RNAi-based transcript knockdowns rather than genomic deletions because deletions could potentially disrupt *cis*-regulatory elements. We thus designed lentiviral vectors that contain RNA polymerase II-transcribed artificial microRNAs (hereafter referred to as amiRNA) with perfect homology to the target sequence to elicit target cleavage. The amiRNAs contain an artificial stem sequence targeting our lncRNA of choice as well as flanking and loop sequences from an endogenous miRNA to allow their processing as pre-miRNA by the RNAi pathway ([Figure S1](#mmc1){ref-type="supplementary-material"}A). As a reference, we used the same strategy to knock down TFs that are well known to regulate gene expression in pancreatic islets as well as five different non-targeting amiRNA sequences as controls.

The lncRNAs selected for knockdown were derived from a short list of 25 lncRNAs that showed (1) a markedly enriched expression in human islets and fluorescence-activated cell sorting (FACS)-purified β cells relative to the exocrine pancreas and a panel of non-pancreatic tissues, (2) expression in the EndoC-βH1 β cell line, and (3) a chromatin profile in human islets that was consistent with an active promoter ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Of these 25 lncRNAs, 12 were shortlisted because they were near a protein-coding gene that has an important function in β cells. The lncRNAs had variable subcellular enrichment patterns ([Figure S1](#mmc1){ref-type="supplementary-material"}B), and eight of the 12 lncRNAs had detectable transcripts in orthologous or syntenic mouse regions ([Table S1](#mmc2){ref-type="supplementary-material"}; [@bib32]). We then screened four amiRNA sequences for each of the 12 lncRNAs and identified two efficient (\>50% knockdown) amiRNAs for seven lncRNAs and one efficient amiRNA sequence for the other five lncRNAs ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Two efficient amiRNAs were also obtained for five essential islet TFs (*HNF1A*, *GLIS3*, *MAFB*, *NKX2.2*, and *PDX1).* We thus transduced EndoC-βH1 cells with lentiviruses expressing each amiRNA. This was done in duplicate or in triplicate for lncRNAs that only had one efficient amiRNA. 80 hr post-transduction, RNA was harvested and hybridized to oligonucleotide microarrays ([Figure 1](#fig1){ref-type="fig"}A). For each target gene, we combined expression data from all knockdowns and compared them to the control transductions with five different control amiRNAs to identify genes that were differentially expressed at a significance level of p \< 10^−3^ (ANOVA) ([Figure 1](#fig1){ref-type="fig"}B).

As expected, knockdown of islet TFs consistently produced transcriptional phenotypes ([Figure 1](#fig1){ref-type="fig"}B). Remarkably, knockdown of 9 of the 12 islet lncRNAs also caused transcriptional changes ([Figure 1](#fig1){ref-type="fig"}B; [Figure S1](#mmc1){ref-type="supplementary-material"}F). A more detailed analysis showed that some of the lncRNAs that presented knockdown phenotypes had visible effects on a neighboring gene, suggesting a possible *cis*-regulatory mechanism, although other such lncRNAs did not appear to affect neighboring genes and may thus function through *trans*-regulatory mechanisms ([Figure 1](#fig1){ref-type="fig"}E; [Figure S1](#mmc1){ref-type="supplementary-material"}G). These loss-of-function experiments with selected lncRNAs therefore suggested that lncRNAs can regulate the expression of pancreatic β cell genes.

Gene silencing using the RNAi pathway can theoretically lead to nonspecific gene deregulation. In our experimental model, a significant nonspecific result would occur when two unrelated amiRNAs elicited changes in a common set of genes that were not observed in the panel of control non-targeting amiRNAs. To assess the likelihood that two unrelated amiRNA sequences elicit such an effect, we studied the five sets of control (non-targeting) amiRNAs, compared all ten possible combinations of two versus three control amiRNAs, and determined the number of differentially expressed genes ([Figure 1](#fig1){ref-type="fig"}C). Likewise, for each TF or lncRNA that had two valid amiRNAs, we compared the two target-specific amiRNAs against all possible combinations of three control amiRNAs ([Figure 1](#fig1){ref-type="fig"}C). As seen in [Figure 1](#fig1){ref-type="fig"}D, control versus control comparisons generated a median of 16 (IQR = 15--22) differentially expressed genes, whereas all five TFs and six of the seven lncRNA knockdowns led to a significantly higher number of differentially expressed genes (Mann-Whitney test, p \< 10^−4^ for all lncRNA/TF versus control comparisons except *HI-LNC75*, p = 0.004, and *HI-LNC76*, p \> 0.5). These results show that the observed phenotypes are unlikely to be caused by unspecific effects of amiRNAs and indicate that the sequence-specific inhibition of selected islet lncRNAs can result in transcriptional changes comparable in magnitude to the inhibition of well-established islet transcriptional regulators.

The primary function of β cells is to synthesize and secrete insulin in response to changes in glucose concentrations. Among the genes that showed functional dependence on lncRNAs, we identified numerous genes that are known to regulate transcription or secretion in β cells, including *RFX6*, *PDX1*, *CACNA1D*, *ATP2A3*, *ROBO1* and *2*, *PDE8A*, *ATP6AP1*, *KCNJ15*, *TRPM3*, *ERO1LB*, and *HADH* ([Figure 2](#fig2){ref-type="fig"}A; [@bib2], [@bib29], [@bib30], [@bib34], [@bib49], [@bib54], [@bib57], [@bib58], [@bib62], [@bib65]). We therefore measured insulin content and glucose-stimulated insulin secretion (GSIS) in T antigen-excised EndoC-βH3 cells after knocking down four lncRNAs that showed the strongest transcriptional phenotypes (*HI-LNC12*, *HI-LNC78*, *HI-LNC80*, and *HI-LNC71*). Congruent with the broad transcriptional phenotype, we observed reduced insulin content and, consequently, impaired glucose-stimulated insulin secretion for *HI-LNC12*, *HI-LNC78*, and *HI-LNC71* knockdowns ([Figure 2](#fig2){ref-type="fig"}B). For *HI-LNC78*, a glucose-regulated islet transcript ([@bib32]) that is orthologous to mouse *Tunar* and zebrafish *megamind (linc-birc6)* lncRNAs ([@bib55]), there was a reduction in GSIS after correcting for the reduction in insulin content (p = 0.002) ([Figure S2](#mmc1){ref-type="supplementary-material"}A). To further validate these effects, the same lncRNAs were downregulated using antisense locked nucleic acid (LNA GapmeRs, Exiqon) GapmeRs, which also led to impaired insulin secretion after knockdown of *HI-LNC12* and *HI-LNC78* ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Taken together, lncRNA knockdown studies identified lncRNAs that modulate gene expression and, consequently, insulin secretion in a human β cell line.

Human Islet lncRNAs and TFs Regulate Common Gene Expression Programs {#sec2.2}
--------------------------------------------------------------------

To gain insight into the expression programs that are regulated by islet-specific lncRNAs and TFs, we compared their knockdown gene expression phenotypes. We first assessed changes in gene expression occurring after knockdown of the different islet TFs and found high Pearson correlation values for all pairwise comparisons (r = 0.4--0.8, p \< 10^−27^) ([Figure 3](#fig3){ref-type="fig"}A; [Figure S3](#mmc1){ref-type="supplementary-material"}). This finding is consistent with the notion that islet-specific TFs often bind to common genomic targets and function in a combinatorial manner ([@bib38], [@bib42], [@bib61]). Interestingly, the transcriptional changes that occurred after the inhibition of several lncRNAs significantly correlated with those observed following inhibition of TFs ([Figure 3](#fig3){ref-type="fig"}A; [Figure S3](#mmc1){ref-type="supplementary-material"}; see also a cluster analysis of TF- and lncRNA-dependent changes in [Figure 3](#fig3){ref-type="fig"}B). Some pairwise comparisons that illustrate this finding include *HI-LNC78*-dependent gene expression changes, which correlated highly with *HNF1A*- and *MAFB*-dependent changes (Pearson's r = 0.87 and 0.89, respectively, p \< 10^−71^), and *HI-LNC15*-dependent changes, which correlated with those occurring after knockdown of *NKX2-2* (r = 0.67, p = 10^−32^) ([Figure 3](#fig3){ref-type="fig"}C). The results from these gene knockdown experiments therefore indicate that selected islet-specific lncRNAs and TFs can regulate common gene expression programs.

Islet TFs and lncRNAs Co-regulate Genes Associated with Enhancer Clusters {#sec2.3}
-------------------------------------------------------------------------

Recent studies have revealed that islet TFs regulate cell-specific transcription by targeting clusters of enhancers and, in particular, clusters with enhancers that are bound by multiple islet TFs ([@bib38]). Enhancer clusters share many features with regulatory domains that have otherwise been defined as "stretch enhancers" or "superenhancers" ([@bib38], [@bib41]). Given that knockdown of islet lncRNAs and TFs suggested that they regulate similar genes, we asked whether islet lncRNAs also regulate enhancer cluster-associated genes. As expected, gene set enrichment analysis (GSEA) showed that genes with islet-enriched expression, genes associated with enhancer clusters, or genes associated with enhancers that are bound by multiple TFs were downregulated after knockdown of all five TFs, whereas this was not observed for ten control sets of genes expressed at similar levels ([Figure 4](#fig4){ref-type="fig"}; [Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Likewise, genes associated with enhancer clusters and those showing islet-specific expression were also enriched among genes that were downregulated after knockdown of *HI-LNC12*, *15*, *30*, *78*, *80, 85*, and *71* ([Figure 4](#fig4){ref-type="fig"}; [Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). These results therefore indicate that islet-specific TFs and lncRNAs often co-regulate genes that are associated with enhancer clusters.

β Cell lncRNAs and TFs Form Part of Islet-Specific Co-expression Networks {#sec2.4}
-------------------------------------------------------------------------

We next used an independent experimental approach to validate the observation that human β cell lncRNAs and TFs regulate common gene expression programs. This involved the analysis of gene modules that show co-expression across a panel of human islet RNA samples. Analogous approaches have been employed to reveal sets of genes that share functional relationships ([@bib13], [@bib24], [@bib36], [@bib47], [@bib51], [@bib52]). We implemented this analysis using weighted gene co-expression analysis (WGCNA) of RNA sequencing (RNA-seq) profiles from 64 human pancreatic islet samples. This identified 25 major gene modules containing more than 100 genes, named M1--M25, that showed highly significant co-expression across human islet samples ([Figure 5](#fig5){ref-type="fig"}A; [Table S2](#mmc3){ref-type="supplementary-material"}). We next determined which co-expression modules contained islet lncRNAs. Rather than using our previously defined set of lncRNAs, this analysis was performed with a set of 2,373 β cell lncRNAs that was newly annotated using ∼5 billion stranded RNA-seq reads pooled from 41 islet samples ([Table S3](#mmc4){ref-type="supplementary-material"}; [Figure S5](#mmc1){ref-type="supplementary-material"}A). β Cell lncRNAs were found to be enriched in seven pancreatic islet co-expression modules (M3, M7, M12, M13, M18, M20, and M21) ([Figure 5](#fig5){ref-type="fig"}B).

We next characterized the nature of these seven lncRNA-enriched co-expression modules. Five of these (M3, M7, M12, M18, and M20) were enriched in genes associated with pancreatic islet enhancer clusters ([Figures 5](#fig5){ref-type="fig"}A--5C, marked in blue). Two other modules (M13 and M21) were enriched for ubiquitously expressed genes involved in mRNA translation and metabolic pathways ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Among the modules enriched in lncRNAs and enhancer clusters, three (M3, M7, and M18) were also enriched in islet-specific TF genes ([Figure 5](#fig5){ref-type="fig"}D), and two of these modules (M3 and M7) contained nine of the 12 lncRNAs that had been knocked down in EndoC-βH1 cells. Module M3, the largest of the seven lncRNA-enriched modules, featured gene ontology (GO) terms associated with prototypical islet cell functions and contained several islet TFs and lncRNAs ([Figure 5](#fig5){ref-type="fig"}E). In keeping with these findings, we found numerous instances of islet lncRNAs and known cell-specific TFs that showed a tight correlation of gene expression levels across human islet samples ([Figure 5](#fig5){ref-type="fig"}F; [Figure S5](#mmc1){ref-type="supplementary-material"}C). These findings thus indicated that β cell-specific lncRNAs, TFs, and genes associated with islet enhancer clusters form part of common expression programs.

Further analysis is consistent with the notion that lncRNAs play a functional role in driving gene expression variation in the lncRNA-enriched co-expression modules. First, the subset of lncRNAs that were shown to regulate an adjacent gene in knockdown studies also exhibited a particular high co-regulation with the adjacent gene across islet samples ([Figure S1](#mmc1){ref-type="supplementary-material"}G). This observation was extended to define 292 lncRNAs that displayed a highly significant (p \< 10^−7^) correlation of expression with an adjacent protein-coding gene in the panel of human islet samples and are thus candidate *cis*-regulatory lncRNAs ([Table S6](#mmc7){ref-type="supplementary-material"}). Second, we analyzed all genes that were significantly downregulated in EndoC-βH1 cells after knocking down *HI-LNC12*, *71*, *78*, and *80* and found that they were also enriched among genes in human islet modules M3, M7, and M18 but not in size-controlled modules ([Figure S5](#mmc1){ref-type="supplementary-material"}D). In summary, co-expression analysis of native human islets corroborated the findings observed with amiRNA-based perturbations in EndoC-βH1 cells and indicated that a group of islet lncRNAs and TFs form part of common transcriptional networks that target clusters of pancreatic islet enhancers ([Figure 5](#fig5){ref-type="fig"}G).

Deregulation of β Cell lncRNAs in Human T2D {#sec2.5}
-------------------------------------------

The identification of functional lncRNAs led us to explore whether some lncRNAs are abnormally expressed in human T2D and might thus be relevant to the pathogenesis of this disease. We therefore analyzed our new set of 2,373 lncRNAs in a recently reported gene expression dataset that includes human islet samples from donors diagnosed with T2D or impaired glucose tolerance (IGT) ([@bib14]). Our results showed that, despite the fact that gene expression across human islet donors is highly variable, the expression of 15 and 100 lncRNAs was significantly altered in islets from T2D and IGT versus non-diabetic donors respectively (adjusted p \< 0.05) ([Figure S6](#mmc1){ref-type="supplementary-material"}A; see [Table S7](#mmc8){ref-type="supplementary-material"} for a complete list). This finding suggests a potential role of functional β cell lncRNAs in driving some of the β cell gene expression changes that are associated with T2D.

*PLUTO* Regulates *PDX1*, an Essential Transcriptional Regulator {#sec2.6}
----------------------------------------------------------------

To explore how β cell lncRNAs can regulate cell-specific transcriptional networks, we focused on *HI-LNC71*, a nuclearly enriched transcript (Figure S1B) that is transcribed from a promoter that is located ∼3 kb upstream of *PDX1*, in an antisense orientation ([Figure S6](#mmc1){ref-type="supplementary-material"}B). PDX1 is an essential transcriptional regulator of pancreas development and β cell function that has been implicated in genetic mechanisms underlying Mendelian and type 2 diabetes ([@bib1], [@bib23], [@bib33], [@bib50]). Based on this genomic location, we renamed *HI-LNC71 PLUTO*, for *PDX1* locus upstream transcript.

The potential importance of *PLUTO* was strengthened by the observation that *PLUTO* was among the most markedly downregulated lncRNAs in islets from T2D or IGT donors (adjusted p value = 0.07 and 0.005, respectively; [Figure 6](#fig6){ref-type="fig"}A; [Figure S6](#mmc1){ref-type="supplementary-material"}B). Interestingly, PDX1 was also downregulated in islets from donors with T2D and IGT ([Figure 6](#fig6){ref-type="fig"}A).

*PLUTO* is a multi-isoform transcript that contains five major exons that span nearly 100 kb, encompassing a cluster of enhancers that make 3D contacts with the *PDX1* promoter in human islets and in EndoC-βH1 cells ([Figure 6](#fig6){ref-type="fig"}B; [Figure S6](#mmc1){ref-type="supplementary-material"}A). This observation suggested that *PLUTO* could affect *cis* regulation of the *PDX1* gene.

To test whether *PLUTO* regulates *PDX1*, we first examined EndoC-βH1 cells after amiRNA-mediated knockdown of *PLUTO* RNA and found reduced *PDX1* mRNA and protein levels ([Figure 6](#fig6){ref-type="fig"}C). Similarly, knockdown of *PLUTO* RNA in dispersed primary human islet cells caused decreased *PDX1* mRNA ([Figure 6](#fig6){ref-type="fig"}D). To validate these experiments through a complementary approach, we used CRISPR interference (CRISPRi), which involves targeting guide RNAs (gRNAs) downstream of a gene's transcriptional initiation site to block its transcription. Two independent gRNAs that targeted a region downstream of the *PLUTO* initiation site efficiently reduced *PLUTO* RNA levels relative to non-targeting gRNAs, and, in both cases, this led to decreased *PDX1* mRNA expression ([Figure 6](#fig6){ref-type="fig"}E). Therefore, perturbing either *PLUTO* RNA levels or its transcription leads to the same inhibitory effect on *PDX1* mRNA.

The mouse *Pdx1* locus also has an islet lncRNA (*Pluto*) that shows only limited sequence homology with human *PLUTO*. *Pluto* is also transcribed from the opposite strand of *Pdx1* but is initiated from a promoter within the first intron of *Pdx1* and, like *PLUTO*, spans a broad regulatory domain upstream of *Pdx1* ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Knockdown of *Pluto* RNA in the mouse β cell line MIN6 also led to decreased *Pdx1* mRNA levels ([Figure S6](#mmc1){ref-type="supplementary-material"}E). These experiments therefore indicated that *PLUTO* regulates *PDX1* mRNA in human β cell lines and primary islet cells, and an analogous effect was observed for the mouse lncRNA ortholog.

Consistent with this regulatory relationship, *PLUTO* and *PDX1* RNA levels are highly correlated across islet samples (Pearson's r = 0.86, p = 10^−15^; [Figure 6](#fig6){ref-type="fig"}F), and knockdown of *PDX1* and *PLUTO* in EndoC-βH1 cells resulted in the deregulation of a shared set of genes ([Figures 6](#fig6){ref-type="fig"}G--6J). Furthermore, *Pluto* and *Pdx1* were found to be regulated with nearly identical dynamics in response to a shift in glucose concentration (4--11 mM) in mouse pancreatic islets ([Figure S6](#mmc1){ref-type="supplementary-material"}D). *PLUTO* and *PDX1* therefore regulate a common program in pancreatic islets, and this is at least in part explained by the fact that *PLUTO* regulates *PDX1.*

*PLUTO* Regulates *PDX1* Transcription and Local 3D Chromatin Structure {#sec2.7}
-----------------------------------------------------------------------

To assess the mechanisms underlying the function of *PLUTO*, we first examined whether *PLUTO* controls the stability or transcription of *PDX1.* Transcriptional inhibition experiments using Actinomycin D showed no significant differences in the stability of *PDX1* mRNA upon *PLUTO* knockdown ([Figure 7](#fig7){ref-type="fig"}A). By contrast, intronic *PDX1* RNA was reduced upon *PLUTO* knockdown, suggesting that *PLUTO* regulates *PDX1* transcription ([Figure 7](#fig7){ref-type="fig"}B).

Because *PLUTO* spans an enhancer cluster, we hypothesized that it could regulate the chromatin state of active enhancers. We thus knocked down *PLUTO* in β cells and measured H3K27 acetylation as well as H3K4 mono- and tri-methylation levels at several enhancers within the cluster. Our results indicate no significant changes in these characteristic active chromatin marks ([Figure S7](#mmc1){ref-type="supplementary-material"}).

We next determined whether *PLUTO* affects the 3D contacts between the enhancer cluster and the *PDX1* promoter. Examination of the *PDX1* locus using quantitative chromatin conformation capture (3C) assays revealed that two far upstream enhancers ([Figure 7](#fig7){ref-type="fig"}C) showed reduced contacts with the *PDX1* promoter after *PLUTO* knockdown ([Figure 7](#fig7){ref-type="fig"}D). These findings therefore show that *PLUTO* regulates the transcription of *PDX1*, a key pancreatic β cell transcriptional regulator, and that this is associated with its ability to promote contacts between the *PDX1* promoter and its enhancer cluster ([Figure 7](#fig7){ref-type="fig"}E).

Discussion {#sec3}
==========

In the current study, we have tested the hypothesis that lncRNAs play a role in cell-specific gene regulation in pancreatic β cells, a cell type that is central in the pathogenesis of human diabetes. We have thus carried out, for the first time, a systematic analysis of the function of a set of human β cell-specific lncRNAs. Our experiments revealed several examples of β cell lncRNAs in which sequence-specific perturbation causes transcriptional and functional phenotypes. We have further shown that β cell-specific lncRNAs and TFs regulate a common transcriptional network. Finally, we have demonstrated that β cell-specific lncRNAs directly or indirectly participate in the regulation of human enhancer clusters, which are the major functional targets of islet-specific transcription factors and key *cis*-regulatory determinants of islet cell transcriptional programs ([@bib38]). Importantly, these conclusions are supported by concordant results from co-expression network analysis and loss of function experiments. These studies should be interpreted in light of previous evidence indicating that a significant fraction of lncRNAs show lineage-specific expression ([@bib7], [@bib12], [@bib16], [@bib19], [@bib22], [@bib32], [@bib39]). Our study extends previous findings by demonstrating a functional role of lncRNAs in lineage-specific TF networks.

Our findings invite the question of what molecular mechanisms underlie the regulatory effects of β cell lncRNAs. LncRNAs have been proposed to control gene expression through diverse molecular mechanisms, including the formation of protein-specific interactions and scaffolds, RNA-DNA or RNA-RNA hybrids, the titration of miRNAs, and the modulation of 3D chromosomal structures ([@bib44], [@bib59]), whereas some transcripts currently defined as lncRNAs can theoretically encode for atypical small peptide sequences ([@bib3]). Our knockdown and co-expression analyses have identified a subset of functional lncRNAs that appear to regulate a nearby gene, suggesting a lncRNA-based *cis*-regulatory mechanism, whereas others are likely to exert *trans*-regulatory effects. We focused on one functional nuclear-enriched β cell lncRNA, *PLUTO*, and found that its function in β cell networks is at least in part due to its ability to elicit an effect on the transcription of its adjacent gene, *PDX1*, which encodes a key β cell transcription factor. Importantly, this was observed for both the mouse and human orthologs, and similar effects were obtained through RNAi suppression or through CRISPR-induced transcriptional interference of *PLUTO*. Our studies further showed that *PLUTO* promotes 3D interactions between the *PDX1* promoter and its upstream enhancer cluster, which is contained within the body of the *PLUTO* gene. We thus propose that *PLUTO* regulates the 3D architecture of the enhancer cluster at the *PDX1* locus. This finding is reminiscent but distinct from earlier examples of non-coding RNA genes that modulate 3D chromosomal structure ([@bib28], [@bib63]). Given that a significant number of lncRNAs are co-expressed with adjacent lineage-specific protein-coding genes, it is possible that the general regulatory paradigm described here is relevant to analogous lncRNA-protein coding gene pairs.

Taken together, our data implicate cell-specific lncRNAs in human β cell transcriptional programs. Given the importance of TFs in the pathophysiology of human diabetes and their role in β cell programming strategies, it now seems reasonable to explore whether β cell lncRNAs also play analogous roles ([@bib4], [@bib15], [@bib64]). The findings reported here therefore strengthen earlier suggestions that defects in β cell lncRNAs might contribute to the pathogenesis of human diabetes ([@bib14], [@bib32]) and warrant an assessment of whether they can be harnessed to promote β cell differentiation, function, or cellular mass.

Experimental Procedures {#sec4}
=======================

Pancreatic Islets {#sec4.1}
-----------------

Human islets used for RNA-seq and chromatin immunoprecipitation sequencing (ChIP-seq) were cultured with CMRL 1066 medium containing 10% fetal calf serum (FCS) before shipment, after which they were cultured for 3 days with RPMI 1640 medium containing 11 mM glucose and supplemented with 10% FCS.

Glucose-Stimulated Insulin Release {#sec4.2}
----------------------------------

Glucose-stimulated insulin release was assayed in EndoC-βH1 or EndoC-βH3 cells as described previously ([@bib5], [@bib43]).

RNA Analysis {#sec4.3}
------------

RNA was isolated with Tripure (Roche) and treated with DNase I (Sigma). qPCR was performed with SYBR green or Taqman probe detection ([@bib56]). See [Table S4](#mmc5){ref-type="supplementary-material"} for oligonucleotide and probe sequences.

amiRNA and CRISPRi Experiments {#sec4.4}
------------------------------

Lentiviral vectors carrying amiRNAs targeting TFs, lncRNAs, and non-targeting control sequences were transduced into the EndoC-βH1 human β cell line as described previously ([@bib10], [@bib43], [@bib45]).

[Figure S1](#mmc1){ref-type="supplementary-material"}A illustrates the vector design. Oligonucleotide sequences are shown in [Table S4](#mmc5){ref-type="supplementary-material"}. Non-transduced cells were assayed in parallel. Cells were harvested 80 hr post transduction for RNA extraction. For transduction of human islets, islets were first dispersed using trypsin-EDTA and gentle agitation. CRISPRi experiments were performed with two gRNAs designed to target *PLUTO* exon 1 or two unrelated intergenic control regions and transfected in EndoC-βH3 cells ([Table S4](#mmc5){ref-type="supplementary-material"}).

Gene Expression Array Analysis {#sec4.5}
------------------------------

RNA was hybridized onto HTA2.0 Affymetrix arrays. RMA normalization was carried out using Expression Console (Affymetrix). Gene-based differential expression analysis was done using Transcriptome Analysis Console (TAC, Affymetrix). Enhancer cluster genes were defined by genes that were associated with clustered islet enhancers that show top 50 percentile binding by TFs (PDX1, FOXA2, NKX2-2, NKX6.1, and MAFB) as defined previously ([@bib38]). Pancreatic islet gene sets used for enrichment analysis are shown in [Table S5](#mmc6){ref-type="supplementary-material"}. A list of islet-enriched genes was generated as those with more than two SDs higher expression in human islets than the average expression in 16 human tissues ([Table S5](#mmc6){ref-type="supplementary-material"}).

Differential Expression in IGT and T2D Islets {#sec4.6}
---------------------------------------------

RNA-seq data have been described previously ([@bib14]). The samples were aligned to the hg19 genome using STAR aligner version 2.3.0 as described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}, quantification was carried out with HTseq-Count 0.6.1, and differential expression analysis of lncRNA genes was done using DEseq2 1.10 ([Table S3](#mmc4){ref-type="supplementary-material"}) using an adjusted p value threshold of 0.05.

3C {#sec4.7}
--

3C and 4C-seq was carried out as described previously ([@bib38], [@bib53]) For real-time PCR quantification, readings were normalized to a control region within the *PDX1* intron. Normalized values are expressed as a fraction of non-targeting amiRNA control sample. See [Table S4](#mmc5){ref-type="supplementary-material"} for oligonucleotide sequences.

Annotation of Islet lncRNAs {#sec4.8}
---------------------------

LncRNAs were annotated through de novo assembly of ∼5 billion stranded paired-end RNA-seq reads from 41 human islet samples, filtered for expression in FACS-purified β cell cells, lack of enrichment in the pancreatic exocrine fraction to exclude acinar contaminants, and the presence of H3K4me3 enrichment in the vicinity of the 5′ end. A more detailed description of the annotation process is provided in the Supplemental Information. Annotations are available in [Table S3](#mmc4){ref-type="supplementary-material"} and can be accessed on a UCSC Genome Browser (GRCh37/hg19) session by selecting "track hubs" and "Human Islet lncRNAs." Alternatively, the track hub can be directly visualized in the UCSC Genome Browser using the following link: <http://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&hubUrl=http://www.imperial.ac.uk/medicine/beta-cell-genome-regulation-laboratory/data/HILNCs/HILNCs.txt&hgS_loadUrlName=http://www.imperial.ac.uk/medicine/beta-cell-genome-regulation-laboratory/data/>.

Network Analysis {#sec4.9}
----------------

The WGCNA(v2) tool was used to build a co-transcriptional network based on mRNAs from 64 human islet RNA-seq samples.
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![Knockdown of Selected β Cell lncRNAs Leads to Transcriptional Phenotypes\
(A) Schematic of the experimental plan. Lentivirally encoded amiRNAs were validated and transduced in duplicate (×2) or triplicate (×3) into ENDOC-βH1 cells as indicated and then analyzed with oligonucleotide expression arrays.\
(B) Differential gene expression analysis revealed genes that show significant up- or downregulation after knockdown of TFs or lncRNAs. For each TF or lncRNA, we combined all replicates transduced with the different target-specific amiRNAs and compared these with all replicates from five non-targeting controls. Differential expression was determined at p \< 10^−3^ (ANOVA).\
(C) We compared gene expression data from all ten possible combinations of three versus two control non-targeting amiRNAs. Similarly, the two independent amiRNAs that target each TF or lncRNA were compared with all ten possible combinations of three control amiRNAs. For this analysis, we only considered the seven lncRNAs that were targeted by two independent amiRNAs.\
(D) Control comparisons result in a low number of differentially regulated genes (average 15 genes), whereas most TF and lncRNA comparisons yield higher numbers of differentially regulated genes. ^∗∗∗^p \< 10^−4^; ^∗∗^p \< 0.01; ns, not significant compared with control comparisons; Mann-Whitney test.\
(E) *HI-LNC15* regulates its neighboring gene, *NKX2.2*, whereas *HI-LNC12* knockdown (KD) does not affect its adjacent active gene, *UNC5A* (left). Further examples are shown in [Figure S1](#mmc1){ref-type="supplementary-material"}G. RNAs were normalized to *TBP* mRNA and expressed relative to control amiRNAs; n = 3, error bars represent SEM; ^∗∗^p \< 0.01, ^∗^p \< 0.05 (Student's t test).](gr1){#fig1}

![Knockdown of lncRNAs Impairs Insulin Secretion\
(A) Examples of genes known to play a role in β cell function regulated by islet lncRNAs.\
(B) Glucose-stimulated insulin secretion was tested on T antigen-excised EndoC-βH3 cells after transduction with amiRNAs targeting the indicated lncRNAs or controls. Secreted or total insulin content was normalized to the number of cells per well and expressed as fold change over control amiRNA treatment at 2.8 mM glucose. Each bar represents an average from two independent amiRNA vectors and 12 separate wells from two independent experiments. Error bars represent SEM; ^∗∗∗^p \< 10^−3^, ^∗∗^p \< 0.01, ^∗^p \< 0.05 (Student's t test).](gr2){#fig2}

![Human Islet TFs and lncRNAs Regulate Common Genes\
(A) Heatmap displaying Pearson r values for all pairwise comparisons of fold changes in gene expression after knockdown of TFs and lncRNAs. Only genes significantly dysregulated at p \< 10^−3^ under at least one condition were included in the analysis.\
(B) Unsupervised clustering analysis of fold change values after knockdown of five TFs and the five lncRNAs that displayed the strongest transcriptional changes. Only genes that were dysregulated at p *\<*10^−3^ in at least one knockdown were selected. Blue represents downregulated and red represents upregulated genes. Controls represent control comparisons as described for [Figure 1](#fig1){ref-type="fig"}.\
(C) Examples of highly correlated transcriptional phenotypes. The plots show fold change values (Log2) after knockdown of the indicated pairs of genes. Only the top 100 most regulated genes for any of the two knockdowns were plotted. Pearson\'s correlation (r) and p values are displayed.](gr3){#fig3}

![LncRNAs Regulate Enhancer Cluster Genes\
GSEA showed that genes that were downregulated upon knockdown of either islet TFs or lncRNAs were enriched in a set of 694 genes that is associated with human islet enhancer clusters (red dots) but not in ten control gene sets (black dots) that were expressed at similar levels as enhancer cluster genes.](gr4){#fig4}

![Islet-Specific Coding and Noncoding RNAs Form Shared Co-expression Modules\
(A) Topological overlap matrix representing co-expression modules that were co-regulated across 64 human islet samples. Modules that were enriched in lncRNAs are marked with squares (hypergeometric test, p \< 10^−2^).\
(B--D) Co-expression modules that showed enrichment in islet lncRNAs (B), islet enhancer cluster (EC)-associated genes (C), or a set of 94 islet-enriched TF genes (D). Five modules (M3, M7, M12, M18, and M20, marked in blue) out of seven modules that were enriched in lncRNAs were also enriched in ECs and TFs.\
(E) Module M3 was enriched in typical islet-specific biological process annotations. Right: examples of islet TFs and lncRNAs in module M3.\
(F) Correlation of the indicated lncRNAs and β cell-specific TF mRNAs across 64 islet samples. *GAPDH* is shown as a non-β cell reference. Pearson's correlation values are displayed in the top left corner. The axes show expression values normalized across 64 islet samples.\
(G) Network diagram illustrating that TFs and lncRNAs often co-regulate the same genes, many of which are associated with enhancer clusters.](gr5){#fig5}

![*PLUTO* Knockdown Decreases *PDX1* mRNA\
(A) Downregulation of *PLUTO* (HI-LNC71) and *PDX1* in islets from donors with T2D or IGT. Differential expression analysis was performed on control (n = 50) versus T2D (n = 10) or IGT (n = 15) samples. Boxplots represent expression normalized to the mean of control samples. Adjusted p values are shown.\
(B) Schematic of the human *PDX1* locus and its associated enhancer cluster. A 4C-seq analysis was designed to identify regions interacting with the *PDX1* promoter region in EndoC-βH1 cells. Red and orange vertical lines depict active and poised islet enhancers, respectively. F and R represent forward and reverse RNA-seq strands, respectively, and scales represent RPM. *PLUTO* (*HI-LNC71*) was generated from a de novo assembly of islet RNA-seq and differs from a transcript annotated in UCSC and RefSeq that originates from a *PDX1* intronic region.\
(C) Downregulation of *PLUTO* or *PDX1* using amiRNAs resulted in reduced *PDX1* mRNA and protein levels. EndoC-βH1 cells were transduced with control (black), *PLUTO* (white), or *PDX1* (turquoise) amiRNA vectors 80 hr prior to harvest. RNA levels were assessed by qPCR, normalized to *TBP*, and expressed as fold over control amiRNA samples (n = 4). For protein quantification, PDX1 levels were first normalized to the average of TBP and H3 levels and then compared with the control amiRNA sample.\
(D) Downregulation of *PLUTO* in human islet cells results in reduced *PDX1* mRNA levels. Islet cells were dispersed and transduced with amiRNA vectors (n = 3) as in (B).\
(E) Downregulation of *PLUTO* in EndoC-βH3 cells using CRISPRi also decreases *PDX1* mRNA. EndoC-βH3 cells were nucleofected with CRISPRi vectors 80 hr prior to harvest. RNA levels were assessed by qPCR and normalized to *TBP* and then to a control CRISPRi sample (n = 3).\
(F) *PDX1* and *PLUTO* RNA levels were highly correlated in 64 human islet samples.\
(G) Knockdown of *PDX1* and *PLUTO* resulted in differential expression of similar genes. Fold change value (Log2) of top 250 dysregulated genes following the *PDX1* knockdown was plotted against the same genes following the *PLUTO* knockdown.\
(H) GSEA showed that genes that were downregulated upon knockdown of *PDX1* and *PLUTO* were enriched in genes whose enhancers were bound by PDX1 (red) in islets but not in ten control gene sets (black) that were expressed at similar levels as PDX1-bound genes.\
(I) Knockdown of *PDX1* and *PLUTO* resulted in differential expression of genes with similar biological process annotations.\
(J) Examples of known *PDX1*-regulated genes that are also co-regulated by *PLUTO* in parallel knockdown experiments. mRNA levels were assessed as in (B). Error bars denote SEM; ^∗∗∗^p \< 10^−3^, ^∗∗^p \< 0.01, ^∗^p \< 0.05 (Student's t test).](gr6){#fig6}

![*PLUTO* Regulates *PDX1* Transcription and 3D Chromatin Structure\
(A) The mRNA stability of *PDX1* was unaffected by *PLUTO* knockdown. *PDX1* mRNA was measured in control and *PLUTO* amiRNA knockdown in EndoC-βH1 cells after Actinomycin D (ActD) treatment (n = 3). mRNA levels are presented as a percentage of levels observed at time = 0.\
(B) Knockdown of *PLUTO* was carried out as in [Figure 6](#fig6){ref-type="fig"}B, and this led to reduced *PDX1* transcription, as assessed by qPCR analysis of intronic *PDX1* RNA levels using hydrolysis probes. Values were normalized to *TBP* mRNA and expressed as fold over the control amiRNA sample (n = 4).\
(C) Schematic of selected epigenomic features of the *PDX1* locus.\
(D) *PLUTO* is required for 3D contacts between the *PDX1* promoter and distal enhancers. 3C analysis revealed that knockdown of *PLUTO* resulted in reduced contacts between the *PDX1* promoter (anchor) and two enhancers (E1 and E2). Interaction signals were normalized to a control region on the *PDX1* intron. CTL represents a negative control region that does not harbor interactions with the *PDX1* promoter. Error bars denote ± SEM, and p values are from a Student's t test.\
(E) *PLUTO* knockdown resulted in impaired 3D contacts between the *PDX1* promoter and its adjacent enhancer cluster, causing reduced *PDX1* transcriptional activity.](gr7){#fig7}
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